Thresholds in Cost-Effectiveness Analysis-More of the Story
To The Editor-Thanks are due to Eichler et al. [1] for their excellent overview of the history and issues concerning the various thresholds used as a benchmark in many cost-effectiveness studies. The international picture they present is especially welcome. I offer the following to complement what Eichler and colleagues reported: Hartke by the National Kidney Foundation and physicians who were also advocating for the entitlement. These reported events, then, suggest that the use of any dollar amount as implying willingness to pay for a medical or health intervention by the federal government-and by extension, the $50,000 threshold-appears to be without basis. Of particular note is how testimony in support of the amendment included dialyzing a patient-who volunteered to do this-before members of the House Ways and Means Committee. Unbeknownst to this legislative audience was that the dialysis session was quickly aborted as the patient went into ventricular tachycardia during the procedure. The legislative audience, however, believed they had witnessed a completed procedure [3, 4] . [6] in their presentation of the "well-year"-a measure of health-related quality of life-and its usefulness to policy makers for making comparisons between various health or medical programs.
Kaplan and Bush present the estimated cost per well-year for several health programs and argue for the use of the well-year for making comparisons among health programs on the basis of their relative efficiency. Programs costing less than $20,000 per well-year are considered "cost effective by current standards;" a program costing $20,000 to $100,000 per wellyear are "possibly controversial, but justifiable by many current examples;" and programs costing greater than $100,000 per well-year are "questionable in comparison with other health care expenditures [6] ." All of the health programs referred to by Kaplan and Bush in their article, such as PKU screening, tuberculin testing, and estrogen therapy for postmenopausal symptoms, among others, are based on previously published studies, save one-hospital renal dialysis, for which estimated cost-utility is presented as much greater than $50,000 per well-year. 2. Hirth et al. [2] used the results of their review of studies estimating the value of life to calculate the implied value of a QALY. Depending on the method used in the original study to calculate the value of life, the reported values of a QALY ranged from $31,000, human capital approach, to $543,000, revealed preference/job risk approach, with a median value of $336,000, all in 2003 US dollars [7] . It is interesting to note that the inflation-adjusted value of $336,000 approximates the upper value of the cost per well-year, $366,000 after adjust-ment for inflation, for an intervention to be considered controversial but justifiable as proposed by Kaplan and Bush.
To summarize, although some allocation decisions made in the UK and Australia seem to point to $50,000 per QALY as a cost-effectiveness threshold, neither the dialysis standard nor Laupacis et al.'s recommended guidelines for technology adoption are the basis for this figure.
The opportunity to offer these remarks is appreciated.-Franklin Laufer, PhD, AIDS Institute, New York State Department of Health.
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